Harnessing Lessons from the Efforts Mitigating the COVID-19 Pandemic
While the world responds to the COVID-19 pandemic, novel influenza viruses continue to be a constant pandemic threat. These viruses, which could appear at any time, can lead to circumstances and ramifications similar to or worse than the current experiences resulting from the COVID-19 pandemic. Both domestic and global efforts, such as the U.S. National Influenza Vaccine Modernization Strategy 2020-2030 and the WHO Global Influenza Strategy 2019-2030, have called for the development of more effective influenza vaccines complemented by modern, adaptable manufacturing technologies that can scale production and meet demand during a pandemic.
The global response to COVID-19 has pushed the boundaries on what is possible for rapid pandemic response in several areas, including vaccine research, development, manufacturing, equitable distribution, allocation, and administration. These unprecedented actions could inform and advance future pandemic and seasonal influenza vaccine preparedness efforts.
Click on the images below for study information, including committee rosters and registration options for public events.
- Overview of Vaccine Science: Establishing Priorities to Improve Influenza Vaccines (April 15)
- Major Barriers to Effective Global Coordination and Financing for Influenza Vaccination- Day 1 (April 9)
- Major Barriers to Effective Global Coordination and Financing for Influenza Vaccination- Day 2 (April 16)
- Researching Novel Therapeutics in a Pandemic: Lessons from COVID-19 (April 22)
- Implementation Science and Non-Vaccine Public Health Measures during COVID-19 (April 23)
- Exploring Influenza Vaccine Critical Inputs, Technologies, and Logistics Day 1 (April 23)
- Exploring Influenza Vaccine Critical Inputs, Technologies, and Logistics Day 2 (April 27)
- Overview of Vaccine Science: Existing Evidence and Lessons from COVID-19 (March 30)
- Identifying Gaps in Influenza Vaccine Manufacturing and Distribution (March 11-19)
- The Current Global Governance Landscape for Influenza Vaccines (March 9-11)
- Introduction to the Vaccine Research and Development Landscape (March 8-10)
- Effectiveness of Non-Vaccine Influenza Control Measures (March 2-5)
The National Academy of Medicine has established an International Committee (IC) in coordination with the U.S. Health and Human Services Office of Global Affairs (OGA) to inform and facilitate its efforts to advance global influenza pandemic preparedness. This International Committee will provide the OGA an iterative, interactive, multi-disciplinary, expert-informed process for assessing the global impact that capabilities, technologies, processes, and policies developed for COVID-19 could have on pandemic and seasonal influenza global preparedness and response, especially regarding vaccine development.
The NAM International Committee will convene domestic and international experts from across sectors (e.g., government, academia, industry, civil society, international public health organizations) and a variety of disciplines (e.g., global public health; infectious disease prevention; influenza vaccine research, development, and manufacturing; pandemic preparedness and response; virology, and immunology).
The IC will take a comprehensive approach to explore the current state of the art and provide recommendations to improve the global design, composition, clinical trials, production, scale-up, regulatory approval, distribution of influenza vaccines, and post-approval surveillance for adverse events. These recommendations will be developed by four concurrent National Academies consensus study committees and released as four consensus reports.
Martin Friede, PhD (co-chair) | Unit Lead, World Health Organization
Prashant Yadav, PhD, MBA (co-chair) | Senior Fellow, Center for Global Development
Ripley Ballou, MD | Principle Investigator, ADVANCE Program, IAVI
Norman W. Baylor, PhD | President and Chief Executive Officer, Biologics Consulting
Thomas Beat Cueni, MS | Director-General, International Federation of Pharmaceutical Manufacturers & Associations
Keiji Fukuda, MD, MPH | Director and Clinical Professor, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong
Patricia Jannet Garcia, MD, PhD, MPH | Professor, School of Public Health and Administration, Cayetano Heredia University
Anuradha Gupta, MBA | Deputy Chief Executive Officer, Gavi, The Vaccine Alliance
Richard Hatchett, MD | Chief Executive Officer, CEPI
Daniel B. Jernigan, MD, MPH | Director, Influenza Division, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention; Captain, USPHS (RET)
Etleva Kadilli, MSc | Director, Supply Division, UNICEF
Lawrence Kerr, PhD | Director, Pandemics and Emerging Threats. U.S. Department of Health & Human Services
Heidi J. Larson, PhD | Director, Vaccine Confidence Project, London School of Hygiene & Tropical Medicine
Peter Sands, MPA | Executive Director, The Global Fund to Fight AIDS, Tuberculosis, and Malaria
John Simpson, MBBS, MFPHM | Head, Emergency Response Department; Deputy Director, Health Protection Directorate, Public Health England
Kanta Subbarao, MBBS, MPH | Director, WHO Collaborating Centre for Reference and Research on Influenza, Melbourne
Beverly Ann Taylor, BSc, PhD | Head of Influenza Scientific Affairs, WHO; IFPMA Lead, Seqirus Vaccines
- U.S. Department of Health & Human Services Office of Global Affairs
- Morgan Kanarek | Chief of Staff
- Johanna Gusman | Program Officer
- Jarrett Nguyen | Senior Program Specialist
- Julie Pavlin | Senior Board Director